A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen
- 06 Apr 2017 Planned initiation date changed from 1 Apr 2017 to 14 Aug 2017.
- 25 Jan 2017 Planned initiation date changed from 1 Feb 2016 to 1 Apr 2017.
- 14 Nov 2016 Planned initiation date changed from 1 Nov 2016 to 1 Feb 2016.